Скачать с ютуб Case study Q&A: Selecting initial treatment regimens for patients with advanced low-risk HL в хорошем качестве

Case study Q&A: Selecting initial treatment regimens for patients with advanced low-risk HL

Dr Stefano Luminari addresses several key points relating to the case presentation of a 23-year-old female presenting with classical Hodgkin lymphoma with nodular sclerosis, stage lVA Selecting initial treatment regimens for patients presenting with advanced low-risk HL The patient presented at diagnosis with a stage IV (lung and suspicion of sacrum) low-risk (IPS 2) nodular sclerosis classical HL. According to data from 2008, the first-line standard treatment for this patient was mainly represented by two options, namely ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, adriamycin (doxorubicin), cyclophosphamide, oncovin (vincristine), procarbazine, prednisone) chemotherapy. The choice of ABVD was based on a lower acute and late toxicity profile of this regimen and on a high probability of achieving a cure with the first treatment. Compared with the BEACOPP option, treatment with ABVD has a higher risk of progression; approximately 30% of patients with advanced disease experience relapse or progression after initial therapy. With effective salvage therapies, however, relapsed/refractory patients following ABVD can be rescued, thus making the risk of death with the ABVD or BEACOPP strategy very similar and equally low.1,2 References 1. Viviani S, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365:203--12. 2. Federico M, et al. BEACOPP or no BEACOPP? Lancet Oncol. 2013 Nov;14(12):e487-8. doi: 10.1016/S1470-2045(13)70483-2. A discussion based on the case study of a 23-year-old female presenting with classical Hodgkin lymphoma with nodular sclerosis, stage lVA. The presentation was made by Dr Stefano Luminari on behalf of www.lymphomahub.com. To see the original case study presentation please visit www.lymphomahub.com.